Document Type
Article
Publication Date
1-1-2009
Abstract
Background: The general enhanced expression of alpha(1)-antichymotrypsin (ACT), clusterin (CLU), alpha(1)-antitrypsin (AAT), haptoglobin beta-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian carcinoma (EOCa) was recently reported. In the present study, we compared the expression of the serum acute-phase proteins (APPs) in the patients according to their stages of cancer. Results: Different altered stage correlative expression of the high abundance serum APPs was demonstrated in sera of the patients studied. While the expression of ACT, HAP and AAT appeared to demonstrate positive correlation with the three initial stages of the cancer, inverse correlation was apparently detected in the expression of LRG and CLU. For patients who were diagnosed with stage IV of the cancer, expression of the serum APPs did not conform to the altered progression changes. Conclusion: Our results highlight the potential prognostic significance of selective high abundance serum APPs in patients with EOCa.
Keywords
Epithelial Ovarian Carcinoma, Endometrial Adenocarcinoma, High Abundance Protein, Squamous Cell Cervical Carcinoma, Release Version
Divisions
fac_med
Publication Title
Journal of Hematology & Oncology
Volume
2
Publisher
BMC
Additional Information
ISI Document Delivery No.: 525SX Times Cited: 6 Cited Reference Count: 32 Cited References: Abdul-Rahman PS, 2007, ELECTROPHORESIS, V28, P1989, DOI 10.1002/elps.200600629 Albert JM, 2007, CANCER EPIDEM BIOMAR, V16, P1845, DOI 10.1158/1055-9965.EPI-07-0146 Baker C, 2007, FRONT BIOSCI, V12, P2821, DOI 10.2741/2275 BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503 Bini L, 1996, ELECTROPHORESIS, V17, P612, DOI 10.1002/elps.1150170333 Chen JH, 2004, P NATL ACAD SCI USA, V101, P17039, DOI 10.1073/pnas.0407992101 Chen Y, 2008, PROTEOME SCI, V6, DOI 10.1186/1477-5956-6-20 Doustjalali SR, 2004, ELECTROPHORESIS, V25, P2392, DOI 10.1002/elps.200305950 Ginath S, 2002, INT J GYNECOL CANCER, V12, P372, DOI 10.1046/j.1525-1438.2002.01007.x Heo SH, 2007, PROTEOMICS, V7, P4292, DOI 10.1002/pmic.200700433 HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106 JACOBS I, 1989, HUM REPROD, V4, P1 Kakisaka T, 2007, J CHROMATOGR B, V852, P257, DOI 10.1016/j.jchromb.2007.01.029 KAPADIA C, 1995, J CLIN LAB ANAL, V9, P123 Kawakami T, 2005, PROTEOMICS, V5, P4287, DOI 10.1002/pmic.200401287 Koomen JM, 2005, CLIN CANCER RES, V11, P1110 KRGER S, 2007, NEOPLASMA, V54, P46 Krieg Rene C, 2002, Technol Cancer Res Treat, V1, P263 Lilja H, 2003, UROLOGY, V62, P27, DOI 10.1016/S0090-4295(03)00775-1 MACDONALD D, 1999, GENE THER, V6, P1512 Miyake H, 2000, CANCER RES, V60, P170 Mohamed E, 2008, ELECTROPHORESIS, V29, P2645, DOI 10.1002/elps.200700828 Okano T, 2006, PROTEOMICS, V6, P3938, DOI 10.1002/pmic.200500883 Schwochau GB, 1998, KIDNEY INT, V53, P1647, DOI 10.1046/j.1523-1755.1998.00902.x Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h Trougakos IP, 2004, ANN NY ACAD SCI, V1019, P206, DOI 10.1196/annals.1297.033 Wozniak A, 2005, EXP ONCOL, V27, P233 Wozniak B, 2008, EUR J GYNAECOL ONCOL, V29, P617 Yu KH, 2005, J PROTEOME RES, V4, P1742, DOI 10.1021/pr0501741 Doustjalali Saeid R, 2006, J Med Invest, V53, P20, DOI 10.2152/jmi.53.20 Zelvyte I, 2004, ANTICANCER RES, V24, P241 Zhao CQ, 2007, NEOPLASIA, V9, P1, DOI 10.1593/neo.06619 Chen, Yeng Lim, Boon-Kiong Hashim, Onn H. University of Malaya; Ministry of Science, Technology and Innovation, Malaysia12-02-03-2021; RG011/09AFR This work was funded by research grants from the University of Malaya (RG011/09AFR) and the Ministry of Science, Technology and Innovation, Malaysia (IRPA grant 12-02-03-2021). Biomed central ltd London